Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy.

Current medicinal chemistry - 1 Jan 2020

Strudel Martina, Festino Lucia, Vanella Vito, Beretta Massimiliano, Marincola Francesco M, Ascierto Paolo A

Abstract excerpt

BACKGROUND: A better understanding of prognostic factors and biomarkers that predict response to treatment is required in order to further improve survival rates in patients with melanoma. Prognostic Factors: The most important histopathological factors prognostic of worse outcomes in melanoma are sentinel lymph node involvement, increased tumor thickness, ulceration and higher mitotic rate. Poorer survival may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mutation

Share to Prognosis

Share to Treatment Outcome

Source

Identifiers

PMID: 31804158
DOI: 10.2174/0929867326666191205160007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy.PMID 31804158Read ↗

Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios.Semantic proximity Read ↗

Programmed Cell Death Ligand 1 Immunohistochemical Expression and Cutaneous Melanoma: A Controversial RelationshipSemantic proximity Read ↗

Unraveling the Wide Spectrum of Melanoma BiomarkersSemantic proximity Read ↗

Prognostic and predictive biomarkers in melanoma: an updateSemantic proximity Read ↗

Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma.Semantic proximity Read ↗

Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.Semantic proximity Read ↗

Evaluation of Prognostic Markers for Progression-Free Survival of Metastatic Melanoma Patients Treated with First-Line Ipilimumab Plus NivolumabSemantic proximity Read ↗

Cutaneous melanoma.Semantic proximity Read ↗

Development of a Metastatic Uveal Melanoma Prognostic risk Score (MUMPS) for use in patients receiving immune checkpoint inhibitorsSemantic proximity Read ↗

Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony?Semantic proximity Read ↗

Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanomaSemantic proximity Read ↗

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.